Ernexa Therapeutics Inc. ERNA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -93.43%
- 1 year
- -95.57%
- Open
- 2.14
- Prev close
- 2.11
- Mkt cap
- 3.22M
- Vol
- 4.49K
- Avg vol
- 50.65K
- EPS
- -13.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.97
- High
- 2.14
- Forward P/E
- -0.03
- Beta
- 7.77
- Short ratio
- 1.07
- Inst. own
- 11.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.7302
- 200-d avg
- 1.58
- 1y target
- 0.00
News
1 week ago globenewswire.com
Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation
2 weeks ago globenewswire.com
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa's platform and member of Ernexa's Scientific…
-
3 weeks ago benzinga.com
Ernexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8
Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center. The meeting will take place October…
3 weeks ago globenewswire.com
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Preclinical data highlighting ERNA-101's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million. Option Care Health (NASDAQ:OPCH) stock…
4 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) stock moved upwards by 56.7% to $0.16 during Friday's pre-market session. Stablecoin Development (AMEX:SDEV) stock rose 30.86% to $4.79. The company's market cap…
1 month ago globenewswire.com
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in…
-
1 month ago benzinga.com
Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed…
1 month ago globenewswire.com
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed…
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The…
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved…
1 month ago globenewswire.com
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector
1 month ago globenewswire.com
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D.
Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics
1 month ago globenewswire.com
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC…
1 month ago globenewswire.com
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass.
2 months ago globenewswire.com
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here
2 months ago globenewswire.com
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance
3 months ago globenewswire.com
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System
3 months ago benzinga.com
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics Inc. (NASDAQ:ERNA) on Wednesday said an independently conducted preclinical study validated the anti-tumor activity of its lead cell therapy candidate, ERNA-101, when combined…
3 months ago benzinga.com
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics reports independent preclinical validation of ERNA-101 with PD-1 therapy ahead of the planned 2026 IND filing.
3 months ago benzinga.com
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views
US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while health care stocks fell 0.4%. Morgan Stanley beat earnings.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million. Catheter Precision…
-
3 months ago benzinga.com
Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced compelling new preclinical data…
3 months ago globenewswire.com
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND
3 months ago globenewswire.com
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated…
4 months ago globenewswire.com
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
4 months ago benzinga.com
Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today highlighted significant progress across…
4 months ago globenewswire.com
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through…
4 months ago globenewswire.com
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology Discussion explores challenges of…
-
5 months ago benzinga.com
Ernexa Therapeutics Announces Progress In Development Of ERNA-101; Hits Multiple Milestones Ahead Of Planned IND Submission In Q3 2026 And First‑In‑Human Study Initiation
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced significant progress in the…
5 months ago globenewswire.com
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
CAMBRIDGE, Mass. , May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
5 months ago benzinga.com
Ernexa Stock Is Jumping Today: What's Going On?
Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA‑101 in ovarian cancer.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
5 months ago benzinga.com
Nasdaq Dips Over 1%; US Inflation Surges To 3.8% In April
US stocks lower, Nasdaq down 1% on Tuesday. Health care shares rise 1.7%. Inflation climbs to 3.8%, hot reading since May 2023. Buzzfeed up 105%, Power Solutions down 36%, FTSE 100 drops 0.3%.
-
5 months ago benzinga.com
Brookline Capital Initiates Coverage On Ernexa Therapeutics with Buy Rating, Announces Price Target of $30
Brookline Capital initiates coverage on Ernexa Therapeutics (NASDAQ:ERNA) with a Buy rating and announces Price Target of $30.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
5 months ago benzinga.com
Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data
Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance…
-
5 months ago benzinga.com
Ernexa Therapeutics Announces Its Preclinical Data From Its ERNA-101 Candidate Demonstrates 100% Long-Term Survival In Syngeneic Ovarian Cancer Models
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced new preclinical data…
-
6 months ago benzinga.com
Ernexa Therapeutics Announces 1-For-25 Reverse Stock Split Effective May 4
The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The…
-
7 months ago benzinga.com
Ernexa Therapeutics ERNA-101 Shows Durable Tumor Regression With PD-1 Blockade In Preclinical Ovarian Cancer Models; IND Submission Planned Q3 2026; First-In-Human Trial Expected Q4 2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancerIND submission for ERNA-101 expected in Q3 2026…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
8 months ago benzinga.com
Why ZIM Integrated Shipping Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Why ZIM Integrated Shipping Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket